Nautilus Biotechnology (NAUT) vs Zentalis Pharmaceuticals (ZNTL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Nautilus Biotechnology (NAUT) has outperformed Zentalis Pharmaceuticals (ZNTL) over the past year, gaining 101.8% versus a gain of 45.9%. Over five years, NAUT leads with a -68.1% price change compared with -96.5% for ZNTL. Nautilus Biotechnology is the larger company by market cap ($286.3 million vs $259.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NAUT | ZNTL |
|---|---|---|
| Share price | $2.25 | $2.64 |
| Market cap | $286.32M | $259.04M |
| 1-day change | +23.63% | +5.18% |
| YTD return | -6.67% | +95.56% |
| 1-year return | +101.77% | +45.86% |
| 5-year return | -68.13% | -96.48% |
| EPS (TTM) | $-0.45 | $-2.07 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.31 | $6.95 |
| 52-week low | $0.84 | $1.21 |
| Distance from 52-week high | -47.80% | -62.01% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +70.22% | +177.65% |
| Average volume | 2.67M | 1.21M |
| Shares outstanding | 127.26M | 98.12M |
| Employees | 127 | 106 |
| Sector | Industrials | Health Care |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NAUT has outperformed ZNTL by 55.9 percentage points over the past year.
- The two companies sit in different sectors: Nautilus Biotechnology in Industrials and Zentalis Pharmaceuticals in Health Care.
About Nautilus Biotechnology
NAUT stock →Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis.
Industrials · Biotechnology: Laboratory Analytical Instruments · 127 employees
About Zentalis Pharmaceuticals
ZNTL stock →Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types.
Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees
NAUT vs ZNTL FAQ
Which is bigger, Nautilus Biotechnology or Zentalis Pharmaceuticals?
Nautilus Biotechnology (NAUT) is larger, with a market capitalization of $286.32M compared with $259.04M for Zentalis Pharmaceuticals (ZNTL).
Which stock has performed better over the past year, NAUT or ZNTL?
NAUT returned +101.77% over the past 12 months, compared with +45.86% for ZNTL (price return, excluding dividends). Past performance does not predict future results.
Are Nautilus Biotechnology and Zentalis Pharmaceuticals in the same industry?
No. Nautilus Biotechnology is in the Industrials sector, while Zentalis Pharmaceuticals is in Health Care.